May 2026
M	T	W	T	F	S	S
	1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up

Christopher Pittman/LinkedIn

Apr 22, 2026, 16:16

Christopher Pittman: Superficial Venous Disease Needs Arterial-Level Follow-Up

Christopher Pittman, Founder and Executive Chairman and Fellowship Program Director at Vein911® Vein Treatment Centers, shared a post on LinkedIn:

”Superficial venous disease patients do not receive the same standardized, longitudinal surveillance culture that is ‘baked in’ to arterial care pathways-despite venous disease being chronic, symptom-driven, and recurrence-prone.

Arterial disease taught us to respect durability – and to systematize follow-up.

In coronaries, procedural/technical success is defined immediately (residual stenosis plus TIMI flow)… and trial performance checks often land at at about 6 months. In PAD, we routinely speak in 1–2 year horizons and report patency accordingly.

But in both arterial beds, we all know the real ‘win’ isn’t a pretty image – it’s the patient outcome: Did the claudication improve? Is function better? Is quality of life better?

Now contrast that with superficial venous disease.

Venous literature often frames ‘technical success’ as percent closure/occlusion of the treated truncal vein over time. Important – but incomplete.

Some of the best venous trials actually put the patient first: in the CLASS trial, 5-year disease-specific quality of life (AVVQ) was a primary endpoint.

Here’s the bigger issue – follow-up culture.

After lower extremity arterial revascularization, longitudinal follow-up and surveillance is standard.

Current PAD guidance even supports ABI and duplex surveillance at 1–3 months, 6 months, 12 months, then annually after endovascular procedures (and similarly after vein bypass).

We monitor because restenosis is common, failure matters, and early detection can change outcomes.

In superficial venous care, early ultrasound follow-up is common (often within weeks) – but long-term surveillance pathways are far less standardized, and even the timing and value of routine post-ablation ultrasound is debated in the literature.

Meanwhile, NICE explicitly acknowledges the lack of an established framework and wide variation in varicose vein management – and reminds us that new varicose veins can develop and multiple sessions may be needed.

If we truly believe venous disease is chronic – and our patients’ symptoms and quality of life prove that it is – then venous patients deserve arterial-level rigor: